nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxepin—ORM1—Vismodegib—skin cancer	0.158	0.228	CbGbCtD
Doxepin—ORM1—Vemurafenib—skin cancer	0.125	0.18	CbGbCtD
Doxepin—CYP1A2—Imiquimod—skin cancer	0.0573	0.0828	CbGbCtD
Doxepin—CYP2C19—Vismodegib—skin cancer	0.0431	0.0622	CbGbCtD
Doxepin—CYP2C9—Vismodegib—skin cancer	0.0358	0.0517	CbGbCtD
Doxepin—ABCB1—Vismodegib—skin cancer	0.0348	0.0502	CbGbCtD
Doxepin—CYP1A2—Vemurafenib—skin cancer	0.0314	0.0454	CbGbCtD
Doxepin—CYP3A4—Temozolomide—skin cancer	0.03	0.0434	CbGbCtD
Doxepin—CYP3A4—Imiquimod—skin cancer	0.03	0.0434	CbGbCtD
Doxepin—CYP2D6—Vemurafenib—skin cancer	0.0259	0.0374	CbGbCtD
Doxepin—CYP1A2—Dacarbazine—skin cancer	0.0241	0.0348	CbGbCtD
Doxepin—CYP3A4—Vismodegib—skin cancer	0.0208	0.0301	CbGbCtD
Doxepin—ABCB1—Dactinomycin—skin cancer	0.0183	0.0264	CbGbCtD
Doxepin—CYP3A4—Vemurafenib—skin cancer	0.0165	0.0238	CbGbCtD
Doxepin—CYP1A2—Fluorouracil—skin cancer	0.0141	0.0204	CbGbCtD
Doxepin—CYP2C9—Fluorouracil—skin cancer	0.0127	0.0184	CbGbCtD
Doxepin—ABCB1—Docetaxel—skin cancer	0.00943	0.0136	CbGbCtD
Doxepin—CYP3A4—Docetaxel—skin cancer	0.00565	0.00815	CbGbCtD
Doxepin—CHRM3—muscle of abdomen—skin cancer	0.00482	0.0947	CbGeAlD
Doxepin—HRH1—nose—skin cancer	0.00372	0.0731	CbGeAlD
Doxepin—CHRM5—skin epidermis—skin cancer	0.00315	0.0619	CbGeAlD
Doxepin—SLC6A2—nerve—skin cancer	0.00148	0.0291	CbGeAlD
Doxepin—HTR2A—hindlimb—skin cancer	0.00146	0.0288	CbGeAlD
Doxepin—DRD2—nerve—skin cancer	0.00135	0.0265	CbGeAlD
Doxepin—HTR2A—appendage—skin cancer	0.00126	0.0247	CbGeAlD
Doxepin—CHRM5—epithelium—skin cancer	0.00103	0.0202	CbGeAlD
Doxepin—HRH2—skin of body—skin cancer	0.00102	0.0201	CbGeAlD
Doxepin—CHRM5—skin of body—skin cancer	0.000975	0.0192	CbGeAlD
Doxepin—ADRA1D—epithelium—skin cancer	0.000917	0.018	CbGeAlD
Doxepin—HTR2A—nerve—skin cancer	0.00089	0.0175	CbGeAlD
Doxepin—CHRM4—head—skin cancer	0.000814	0.016	CbGeAlD
Doxepin—HTR2A—endothelium—skin cancer	0.000758	0.0149	CbGeAlD
Doxepin—KCNH2—nipple—skin cancer	0.000755	0.0148	CbGeAlD
Doxepin—ADRA2C—nipple—skin cancer	0.000745	0.0146	CbGeAlD
Doxepin—HTR6—head—skin cancer	0.000729	0.0143	CbGeAlD
Doxepin—HTR2A—blood vessel—skin cancer	0.000699	0.0137	CbGeAlD
Doxepin—ADRA1D—female reproductive system—skin cancer	0.000681	0.0134	CbGeAlD
Doxepin—HRH2—head—skin cancer	0.000666	0.0131	CbGeAlD
Doxepin—CYP1A2—nipple—skin cancer	0.000647	0.0127	CbGeAlD
Doxepin—CHRM5—head—skin cancer	0.000636	0.0125	CbGeAlD
Doxepin—HTR2B—skin of body—skin cancer	0.000606	0.0119	CbGeAlD
Doxepin—HRH1—nipple—skin cancer	0.000605	0.0119	CbGeAlD
Doxepin—ADRA2A—nipple—skin cancer	0.000594	0.0117	CbGeAlD
Doxepin—ADRA1B—head—skin cancer	0.000582	0.0114	CbGeAlD
Doxepin—ADRA1D—head—skin cancer	0.000569	0.0112	CbGeAlD
Doxepin—ORM1—female reproductive system—skin cancer	0.000561	0.011	CbGeAlD
Doxepin—ADRA1A—epithelium—skin cancer	0.000526	0.0103	CbGeAlD
Doxepin—HTR2C—female reproductive system—skin cancer	0.000504	0.00991	CbGeAlD
Doxepin—HTR2A—neck—skin cancer	0.0005	0.00983	CbGeAlD
Doxepin—SLC6A4—female reproductive system—skin cancer	0.000478	0.00939	CbGeAlD
Doxepin—CHRM1—female reproductive system—skin cancer	0.000476	0.00936	CbGeAlD
Doxepin—HTR2B—female reproductive system—skin cancer	0.000473	0.00931	CbGeAlD
Doxepin—HRH2—lymph node—skin cancer	0.000466	0.00917	CbGeAlD
Doxepin—ABCB1—blood vessel—skin cancer	0.000458	0.00901	CbGeAlD
Doxepin—CHRM2—head—skin cancer	0.000437	0.00859	CbGeAlD
Doxepin—ADRA2C—mammalian vulva—skin cancer	0.000435	0.00855	CbGeAlD
Doxepin—HRH1—connective tissue—skin cancer	0.000429	0.00844	CbGeAlD
Doxepin—CHRM3—female reproductive system—skin cancer	0.000426	0.00837	CbGeAlD
Doxepin—ADRA2A—connective tissue—skin cancer	0.000422	0.00829	CbGeAlD
Doxepin—HTR2C—head—skin cancer	0.000421	0.00828	CbGeAlD
Doxepin—SLC6A2—female reproductive system—skin cancer	0.000421	0.00827	CbGeAlD
Doxepin—HRH1—epithelium—skin cancer	0.000408	0.00801	CbGeAlD
Doxepin—ADRA1A—lymphoid tissue—skin cancer	0.000405	0.00797	CbGeAlD
Doxepin—SLC6A4—head—skin cancer	0.000399	0.00785	CbGeAlD
Doxepin—CHRM1—head—skin cancer	0.000398	0.00782	CbGeAlD
Doxepin—HTR2B—head—skin cancer	0.000396	0.00778	CbGeAlD
Doxepin—KCNH2—female reproductive system—skin cancer	0.000378	0.00742	CbGeAlD
Doxepin—HTR2A—connective tissue—skin cancer	0.000358	0.00705	CbGeAlD
Doxepin—CHRM3—head—skin cancer	0.000356	0.007	CbGeAlD
Doxepin—HTR1A—head—skin cancer	0.000354	0.00697	CbGeAlD
Doxepin—HRH1—mammalian vulva—skin cancer	0.000353	0.00695	CbGeAlD
Doxepin—SLC6A2—head—skin cancer	0.000351	0.00691	CbGeAlD
Doxepin—ADRA2A—mammalian vulva—skin cancer	0.000347	0.00683	CbGeAlD
Doxepin—HTR2A—epithelium—skin cancer	0.00034	0.00669	CbGeAlD
Doxepin—ORM1—lymph node—skin cancer	0.000328	0.00645	CbGeAlD
Doxepin—ADRA1A—head—skin cancer	0.000327	0.00642	CbGeAlD
Doxepin—DRD2—head—skin cancer	0.00032	0.0063	CbGeAlD
Doxepin—KCNH2—head—skin cancer	0.000316	0.0062	CbGeAlD
Doxepin—ADRA2C—head—skin cancer	0.000311	0.00612	CbGeAlD
Doxepin—CYP2C9—female reproductive system—skin cancer	0.000307	0.00603	CbGeAlD
Doxepin—HRH1—female reproductive system—skin cancer	0.000303	0.00595	CbGeAlD
Doxepin—ADRA2A—female reproductive system—skin cancer	0.000297	0.00585	CbGeAlD
Doxepin—HTR2B—lymph node—skin cancer	0.000277	0.00544	CbGeAlD
Doxepin—Angiopathy—Temozolomide—skin cancer	0.000272	0.00122	CcSEcCtD
Doxepin—Ataxia—Docetaxel—skin cancer	0.000271	0.00121	CcSEcCtD
Doxepin—Immune system disorder—Temozolomide—skin cancer	0.000271	0.00121	CcSEcCtD
Doxepin—Mediastinal disorder—Temozolomide—skin cancer	0.00027	0.00121	CcSEcCtD
Doxepin—Cough—Bleomycin—skin cancer	0.00027	0.00121	CcSEcCtD
Doxepin—Chills—Temozolomide—skin cancer	0.000269	0.0012	CcSEcCtD
Doxepin—Ill-defined disorder—Dactinomycin—skin cancer	0.000268	0.0012	CcSEcCtD
Doxepin—Anaemia—Dactinomycin—skin cancer	0.000267	0.00119	CcSEcCtD
Doxepin—Vomiting—Vemurafenib—skin cancer	0.000265	0.00118	CcSEcCtD
Doxepin—Alopecia—Temozolomide—skin cancer	0.000265	0.00118	CcSEcCtD
Doxepin—Chest pain—Bleomycin—skin cancer	0.000263	0.00118	CcSEcCtD
Doxepin—Myalgia—Bleomycin—skin cancer	0.000263	0.00118	CcSEcCtD
Doxepin—Rash—Vemurafenib—skin cancer	0.000263	0.00117	CcSEcCtD
Doxepin—Mental disorder—Temozolomide—skin cancer	0.000263	0.00117	CcSEcCtD
Doxepin—Dermatitis—Vemurafenib—skin cancer	0.000262	0.00117	CcSEcCtD
Doxepin—Hypersensitivity—Imiquimod—skin cancer	0.000262	0.00117	CcSEcCtD
Doxepin—Headache—Vemurafenib—skin cancer	0.000261	0.00117	CcSEcCtD
Doxepin—Malnutrition—Temozolomide—skin cancer	0.000261	0.00117	CcSEcCtD
Doxepin—Erythema—Temozolomide—skin cancer	0.000261	0.00117	CcSEcCtD
Doxepin—Breast disorder—Docetaxel—skin cancer	0.00026	0.00116	CcSEcCtD
Doxepin—Discomfort—Bleomycin—skin cancer	0.00026	0.00116	CcSEcCtD
Doxepin—Malaise—Dactinomycin—skin cancer	0.00026	0.00116	CcSEcCtD
Doxepin—Cramp muscle—Docetaxel—skin cancer	0.000259	0.00116	CcSEcCtD
Doxepin—Leukopenia—Dactinomycin—skin cancer	0.000258	0.00115	CcSEcCtD
Doxepin—Nasopharyngitis—Docetaxel—skin cancer	0.000258	0.00115	CcSEcCtD
Doxepin—Dysgeusia—Temozolomide—skin cancer	0.000256	0.00114	CcSEcCtD
Doxepin—Asthenia—Imiquimod—skin cancer	0.000255	0.00114	CcSEcCtD
Doxepin—Confusional state—Bleomycin—skin cancer	0.000255	0.00114	CcSEcCtD
Doxepin—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000254	0.00114	CcSEcCtD
Doxepin—HRH1—head—skin cancer	0.000253	0.00497	CbGeAlD
Doxepin—HTR2A—female reproductive system—skin cancer	0.000253	0.00497	CbGeAlD
Doxepin—Oedema—Bleomycin—skin cancer	0.000252	0.00113	CcSEcCtD
Doxepin—Back pain—Temozolomide—skin cancer	0.000252	0.00113	CcSEcCtD
Doxepin—Pruritus—Imiquimod—skin cancer	0.000251	0.00112	CcSEcCtD
Doxepin—Infection—Bleomycin—skin cancer	0.000251	0.00112	CcSEcCtD
Doxepin—ADRA2A—head—skin cancer	0.000248	0.00488	CbGeAlD
Doxepin—Nausea—Vemurafenib—skin cancer	0.000248	0.00111	CcSEcCtD
Doxepin—Thrombocytopenia—Bleomycin—skin cancer	0.000247	0.00111	CcSEcCtD
Doxepin—Arrhythmia—Fluorouracil—skin cancer	0.000247	0.0011	CcSEcCtD
Doxepin—SLC6A2—lymph node—skin cancer	0.000246	0.00484	CbGeAlD
Doxepin—Vision blurred—Temozolomide—skin cancer	0.000246	0.0011	CcSEcCtD
Doxepin—Myalgia—Dactinomycin—skin cancer	0.000246	0.0011	CcSEcCtD
Doxepin—Tremor—Temozolomide—skin cancer	0.000244	0.00109	CcSEcCtD
Doxepin—Alopecia—Fluorouracil—skin cancer	0.000244	0.00109	CcSEcCtD
Doxepin—Diarrhoea—Imiquimod—skin cancer	0.000243	0.00109	CcSEcCtD
Doxepin—Discomfort—Dactinomycin—skin cancer	0.000243	0.00108	CcSEcCtD
Doxepin—Ill-defined disorder—Temozolomide—skin cancer	0.000242	0.00108	CcSEcCtD
Doxepin—Anaemia—Temozolomide—skin cancer	0.000241	0.00108	CcSEcCtD
Doxepin—Anorexia—Bleomycin—skin cancer	0.000241	0.00108	CcSEcCtD
Doxepin—Erythema—Fluorouracil—skin cancer	0.00024	0.00107	CcSEcCtD
Doxepin—Agitation—Temozolomide—skin cancer	0.00024	0.00107	CcSEcCtD
Doxepin—Pancytopenia—Docetaxel—skin cancer	0.000237	0.00106	CcSEcCtD
Doxepin—Hypotension—Bleomycin—skin cancer	0.000236	0.00105	CcSEcCtD
Doxepin—Oedema—Dactinomycin—skin cancer	0.000235	0.00105	CcSEcCtD
Doxepin—Malaise—Temozolomide—skin cancer	0.000235	0.00105	CcSEcCtD
Doxepin—Dizziness—Imiquimod—skin cancer	0.000235	0.00105	CcSEcCtD
Doxepin—Vertigo—Temozolomide—skin cancer	0.000234	0.00105	CcSEcCtD
Doxepin—CYP3A4—female reproductive system—skin cancer	0.000234	0.0046	CbGeAlD
Doxepin—Infection—Dactinomycin—skin cancer	0.000234	0.00105	CcSEcCtD
Doxepin—Leukopenia—Temozolomide—skin cancer	0.000234	0.00104	CcSEcCtD
Doxepin—Palpitations—Temozolomide—skin cancer	0.000231	0.00103	CcSEcCtD
Doxepin—Thrombocytopenia—Dactinomycin—skin cancer	0.000231	0.00103	CcSEcCtD
Doxepin—CYP2D6—female reproductive system—skin cancer	0.00023	0.00453	CbGeAlD
Doxepin—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00023	0.00103	CcSEcCtD
Doxepin—Cough—Temozolomide—skin cancer	0.000228	0.00102	CcSEcCtD
Doxepin—Paraesthesia—Bleomycin—skin cancer	0.000227	0.00101	CcSEcCtD
Doxepin—Weight increased—Docetaxel—skin cancer	0.000227	0.00101	CcSEcCtD
Doxepin—Vision blurred—Fluorouracil—skin cancer	0.000227	0.00101	CcSEcCtD
Doxepin—Convulsion—Temozolomide—skin cancer	0.000226	0.00101	CcSEcCtD
Doxepin—Vomiting—Imiquimod—skin cancer	0.000226	0.00101	CcSEcCtD
Doxepin—Hypertension—Temozolomide—skin cancer	0.000225	0.00101	CcSEcCtD
Doxepin—Dyspnoea—Bleomycin—skin cancer	0.000225	0.00101	CcSEcCtD
Doxepin—Anorexia—Dactinomycin—skin cancer	0.000224	0.001	CcSEcCtD
Doxepin—Rash—Imiquimod—skin cancer	0.000224	0.001	CcSEcCtD
Doxepin—Dermatitis—Imiquimod—skin cancer	0.000224	0.001	CcSEcCtD
Doxepin—Pneumonia—Docetaxel—skin cancer	0.000223	0.000998	CcSEcCtD
Doxepin—ABCB1—epithelium—skin cancer	0.000223	0.00438	CbGeAlD
Doxepin—Headache—Imiquimod—skin cancer	0.000223	0.000995	CcSEcCtD
Doxepin—Anaemia—Fluorouracil—skin cancer	0.000222	0.000993	CcSEcCtD
Doxepin—Arthralgia—Temozolomide—skin cancer	0.000222	0.000993	CcSEcCtD
Doxepin—Myalgia—Temozolomide—skin cancer	0.000222	0.000993	CcSEcCtD
Doxepin—Infestation—Docetaxel—skin cancer	0.000222	0.000993	CcSEcCtD
Doxepin—Infestation NOS—Docetaxel—skin cancer	0.000222	0.000993	CcSEcCtD
Doxepin—Anxiety—Temozolomide—skin cancer	0.000221	0.00099	CcSEcCtD
Doxepin—KCNH2—lymph node—skin cancer	0.000221	0.00434	CbGeAlD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000221	0.000986	CcSEcCtD
Doxepin—Discomfort—Temozolomide—skin cancer	0.000219	0.000981	CcSEcCtD
Doxepin—Decreased appetite—Bleomycin—skin cancer	0.000219	0.000981	CcSEcCtD
Doxepin—ADRA2C—lymph node—skin cancer	0.000218	0.00429	CbGeAlD
Doxepin—Neuropathy peripheral—Docetaxel—skin cancer	0.000218	0.000973	CcSEcCtD
Doxepin—Dry mouth—Temozolomide—skin cancer	0.000217	0.000971	CcSEcCtD
Doxepin—Stomatitis—Docetaxel—skin cancer	0.000216	0.000968	CcSEcCtD
Doxepin—Jaundice—Docetaxel—skin cancer	0.000216	0.000968	CcSEcCtD
Doxepin—Pain—Bleomycin—skin cancer	0.000216	0.000965	CcSEcCtD
Doxepin—Leukopenia—Fluorouracil—skin cancer	0.000215	0.000962	CcSEcCtD
Doxepin—Confusional state—Temozolomide—skin cancer	0.000215	0.00096	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000215	0.000959	CcSEcCtD
Doxepin—Oedema—Temozolomide—skin cancer	0.000213	0.000952	CcSEcCtD
Doxepin—Infection—Temozolomide—skin cancer	0.000212	0.000946	CcSEcCtD
Doxepin—HTR2A—head—skin cancer	0.000211	0.00415	CbGeAlD
Doxepin—Nausea—Imiquimod—skin cancer	0.000211	0.000944	CcSEcCtD
Doxepin—Hepatobiliary disease—Docetaxel—skin cancer	0.00021	0.000939	CcSEcCtD
Doxepin—Nervous system disorder—Temozolomide—skin cancer	0.000209	0.000934	CcSEcCtD
Doxepin—Thrombocytopenia—Temozolomide—skin cancer	0.000209	0.000932	CcSEcCtD
Doxepin—Convulsion—Fluorouracil—skin cancer	0.000208	0.000931	CcSEcCtD
Doxepin—Feeling abnormal—Bleomycin—skin cancer	0.000208	0.00093	CcSEcCtD
Doxepin—Agranulocytosis—Docetaxel—skin cancer	0.000207	0.000926	CcSEcCtD
Doxepin—Skin disorder—Temozolomide—skin cancer	0.000207	0.000925	CcSEcCtD
Doxepin—Hyperhidrosis—Temozolomide—skin cancer	0.000206	0.00092	CcSEcCtD
Doxepin—Chest pain—Fluorouracil—skin cancer	0.000205	0.000915	CcSEcCtD
Doxepin—Myalgia—Fluorouracil—skin cancer	0.000205	0.000915	CcSEcCtD
Doxepin—Decreased appetite—Dactinomycin—skin cancer	0.000205	0.000915	CcSEcCtD
Doxepin—Fatigue—Dactinomycin—skin cancer	0.000203	0.000907	CcSEcCtD
Doxepin—Anorexia—Temozolomide—skin cancer	0.000203	0.000907	CcSEcCtD
Doxepin—Discomfort—Fluorouracil—skin cancer	0.000202	0.000904	CcSEcCtD
Doxepin—Pain—Dactinomycin—skin cancer	0.000201	0.0009	CcSEcCtD
Doxepin—Urticaria—Bleomycin—skin cancer	0.000201	0.000897	CcSEcCtD
Doxepin—Body temperature increased—Bleomycin—skin cancer	0.0002	0.000892	CcSEcCtD
Doxepin—Hepatitis—Docetaxel—skin cancer	0.000199	0.000891	CcSEcCtD
Doxepin—Hypoaesthesia—Docetaxel—skin cancer	0.000198	0.000887	CcSEcCtD
Doxepin—Confusional state—Fluorouracil—skin cancer	0.000198	0.000884	CcSEcCtD
Doxepin—Pharyngitis—Docetaxel—skin cancer	0.000198	0.000884	CcSEcCtD
Doxepin—Urinary tract disorder—Docetaxel—skin cancer	0.000197	0.00088	CcSEcCtD
Doxepin—Oedema peripheral—Docetaxel—skin cancer	0.000196	0.000878	CcSEcCtD
Doxepin—Oedema—Fluorouracil—skin cancer	0.000196	0.000877	CcSEcCtD
Doxepin—Connective tissue disorder—Docetaxel—skin cancer	0.000196	0.000876	CcSEcCtD
Doxepin—Urethral disorder—Docetaxel—skin cancer	0.000195	0.000874	CcSEcCtD
Doxepin—Infection—Fluorouracil—skin cancer	0.000195	0.000871	CcSEcCtD
Doxepin—Feeling abnormal—Dactinomycin—skin cancer	0.000194	0.000867	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000194	0.000867	CcSEcCtD
Doxepin—ABCB1—mammalian vulva—skin cancer	0.000193	0.0038	CbGeAlD
Doxepin—Insomnia—Temozolomide—skin cancer	0.000193	0.000861	CcSEcCtD
Doxepin—Gastrointestinal pain—Dactinomycin—skin cancer	0.000193	0.000861	CcSEcCtD
Doxepin—Nervous system disorder—Fluorouracil—skin cancer	0.000192	0.00086	CcSEcCtD
Doxepin—CYP2D6—head—skin cancer	0.000192	0.00378	CbGeAlD
Doxepin—Thrombocytopenia—Fluorouracil—skin cancer	0.000192	0.000859	CcSEcCtD
Doxepin—Tachycardia—Fluorouracil—skin cancer	0.000191	0.000856	CcSEcCtD
Doxepin—Paraesthesia—Temozolomide—skin cancer	0.000191	0.000855	CcSEcCtD
Doxepin—Dyspnoea—Temozolomide—skin cancer	0.00019	0.000849	CcSEcCtD
Doxepin—Somnolence—Temozolomide—skin cancer	0.000189	0.000846	CcSEcCtD
Doxepin—Dyspepsia—Temozolomide—skin cancer	0.000187	0.000838	CcSEcCtD
Doxepin—Anorexia—Fluorouracil—skin cancer	0.000187	0.000836	CcSEcCtD
Doxepin—Eye disorder—Docetaxel—skin cancer	0.000186	0.000833	CcSEcCtD
Doxepin—Abdominal pain—Dactinomycin—skin cancer	0.000186	0.000832	CcSEcCtD
Doxepin—Body temperature increased—Dactinomycin—skin cancer	0.000186	0.000832	CcSEcCtD
Doxepin—Hypersensitivity—Bleomycin—skin cancer	0.000186	0.000831	CcSEcCtD
Doxepin—Decreased appetite—Temozolomide—skin cancer	0.000185	0.000828	CcSEcCtD
Doxepin—Flushing—Docetaxel—skin cancer	0.000185	0.000827	CcSEcCtD
Doxepin—Cardiac disorder—Docetaxel—skin cancer	0.000185	0.000827	CcSEcCtD
Doxepin—Gastrointestinal disorder—Temozolomide—skin cancer	0.000184	0.000822	CcSEcCtD
Doxepin—Fatigue—Temozolomide—skin cancer	0.000184	0.000821	CcSEcCtD
Doxepin—Hypotension—Fluorouracil—skin cancer	0.000183	0.00082	CcSEcCtD
Doxepin—Pain—Temozolomide—skin cancer	0.000182	0.000814	CcSEcCtD
Doxepin—Constipation—Temozolomide—skin cancer	0.000182	0.000814	CcSEcCtD
Doxepin—Asthenia—Bleomycin—skin cancer	0.000181	0.00081	CcSEcCtD
Doxepin—Angiopathy—Docetaxel—skin cancer	0.000181	0.000808	CcSEcCtD
Doxepin—Immune system disorder—Docetaxel—skin cancer	0.00018	0.000805	CcSEcCtD
Doxepin—Mediastinal disorder—Docetaxel—skin cancer	0.00018	0.000803	CcSEcCtD
Doxepin—Chills—Docetaxel—skin cancer	0.000179	0.0008	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000179	0.000799	CcSEcCtD
Doxepin—Pruritus—Bleomycin—skin cancer	0.000179	0.000798	CcSEcCtD
Doxepin—Arrhythmia—Docetaxel—skin cancer	0.000178	0.000796	CcSEcCtD
Doxepin—Insomnia—Fluorouracil—skin cancer	0.000177	0.000793	CcSEcCtD
Doxepin—HRH1—lymph node—skin cancer	0.000177	0.00348	CbGeAlD
Doxepin—Paraesthesia—Fluorouracil—skin cancer	0.000176	0.000788	CcSEcCtD
Doxepin—Alopecia—Docetaxel—skin cancer	0.000176	0.000787	CcSEcCtD
Doxepin—Feeling abnormal—Temozolomide—skin cancer	0.000175	0.000785	CcSEcCtD
Doxepin—Dyspnoea—Fluorouracil—skin cancer	0.000175	0.000782	CcSEcCtD
Doxepin—Mental disorder—Docetaxel—skin cancer	0.000175	0.000781	CcSEcCtD
Doxepin—Somnolence—Fluorouracil—skin cancer	0.000174	0.00078	CcSEcCtD
Doxepin—Gastrointestinal pain—Temozolomide—skin cancer	0.000174	0.000778	CcSEcCtD
Doxepin—ADRA2A—lymph node—skin cancer	0.000174	0.00342	CbGeAlD
Doxepin—Erythema—Docetaxel—skin cancer	0.000174	0.000776	CcSEcCtD
Doxepin—Malnutrition—Docetaxel—skin cancer	0.000174	0.000776	CcSEcCtD
Doxepin—Hypersensitivity—Dactinomycin—skin cancer	0.000173	0.000775	CcSEcCtD
Doxepin—Dyspepsia—Fluorouracil—skin cancer	0.000173	0.000772	CcSEcCtD
Doxepin—ABCB1—lymphoid tissue—skin cancer	0.000172	0.00338	CbGeAlD
Doxepin—Decreased appetite—Fluorouracil—skin cancer	0.000171	0.000763	CcSEcCtD
Doxepin—Dysgeusia—Docetaxel—skin cancer	0.00017	0.00076	CcSEcCtD
Doxepin—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000169	0.000757	CcSEcCtD
Doxepin—Urticaria—Temozolomide—skin cancer	0.000169	0.000756	CcSEcCtD
Doxepin—Asthenia—Dactinomycin—skin cancer	0.000169	0.000755	CcSEcCtD
Doxepin—Abdominal pain—Temozolomide—skin cancer	0.000168	0.000753	CcSEcCtD
Doxepin—Body temperature increased—Temozolomide—skin cancer	0.000168	0.000753	CcSEcCtD
Doxepin—Back pain—Docetaxel—skin cancer	0.000168	0.00075	CcSEcCtD
Doxepin—Pain—Fluorouracil—skin cancer	0.000168	0.00075	CcSEcCtD
Doxepin—Muscle spasms—Docetaxel—skin cancer	0.000167	0.000746	CcSEcCtD
Doxepin—ABCB1—female reproductive system—skin cancer	0.000166	0.00326	CbGeAlD
Doxepin—Feeling abnormal—Fluorouracil—skin cancer	0.000162	0.000723	CcSEcCtD
Doxepin—Diarrhoea—Dactinomycin—skin cancer	0.000161	0.00072	CcSEcCtD
Doxepin—Vomiting—Bleomycin—skin cancer	0.000161	0.000718	CcSEcCtD
Doxepin—Anaemia—Docetaxel—skin cancer	0.00016	0.000717	CcSEcCtD
Doxepin—Rash—Bleomycin—skin cancer	0.000159	0.000712	CcSEcCtD
Doxepin—Dermatitis—Bleomycin—skin cancer	0.000159	0.000711	CcSEcCtD
Doxepin—Hypersensitivity—Temozolomide—skin cancer	0.000157	0.000701	CcSEcCtD
Doxepin—Urticaria—Fluorouracil—skin cancer	0.000156	0.000697	CcSEcCtD
Doxepin—Syncope—Docetaxel—skin cancer	0.000156	0.000696	CcSEcCtD
Doxepin—Leukopenia—Docetaxel—skin cancer	0.000155	0.000694	CcSEcCtD
Doxepin—Body temperature increased—Fluorouracil—skin cancer	0.000155	0.000693	CcSEcCtD
Doxepin—Palpitations—Docetaxel—skin cancer	0.000153	0.000686	CcSEcCtD
Doxepin—Asthenia—Temozolomide—skin cancer	0.000153	0.000683	CcSEcCtD
Doxepin—Loss of consciousness—Docetaxel—skin cancer	0.000153	0.000682	CcSEcCtD
Doxepin—Cough—Docetaxel—skin cancer	0.000151	0.000677	CcSEcCtD
Doxepin—Pruritus—Temozolomide—skin cancer	0.000151	0.000674	CcSEcCtD
Doxepin—Convulsion—Docetaxel—skin cancer	0.00015	0.000672	CcSEcCtD
Doxepin—Nausea—Bleomycin—skin cancer	0.00015	0.00067	CcSEcCtD
Doxepin—Hypertension—Docetaxel—skin cancer	0.00015	0.00067	CcSEcCtD
Doxepin—Vomiting—Dactinomycin—skin cancer	0.00015	0.000669	CcSEcCtD
Doxepin—Rash—Dactinomycin—skin cancer	0.000148	0.000664	CcSEcCtD
Doxepin—Chest pain—Docetaxel—skin cancer	0.000148	0.00066	CcSEcCtD
Doxepin—Arthralgia—Docetaxel—skin cancer	0.000148	0.00066	CcSEcCtD
Doxepin—Myalgia—Docetaxel—skin cancer	0.000148	0.00066	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000147	0.000656	CcSEcCtD
Doxepin—Diarrhoea—Temozolomide—skin cancer	0.000146	0.000651	CcSEcCtD
Doxepin—Hypersensitivity—Fluorouracil—skin cancer	0.000145	0.000646	CcSEcCtD
Doxepin—Dry mouth—Docetaxel—skin cancer	0.000144	0.000646	CcSEcCtD
Doxepin—Confusional state—Docetaxel—skin cancer	0.000143	0.000638	CcSEcCtD
Doxepin—Oedema—Docetaxel—skin cancer	0.000142	0.000633	CcSEcCtD
Doxepin—Dizziness—Temozolomide—skin cancer	0.000141	0.00063	CcSEcCtD
Doxepin—Infection—Docetaxel—skin cancer	0.000141	0.000629	CcSEcCtD
Doxepin—Nausea—Dactinomycin—skin cancer	0.00014	0.000625	CcSEcCtD
Doxepin—Shock—Docetaxel—skin cancer	0.000139	0.000623	CcSEcCtD
Doxepin—Nervous system disorder—Docetaxel—skin cancer	0.000139	0.000621	CcSEcCtD
Doxepin—Pruritus—Fluorouracil—skin cancer	0.000139	0.000621	CcSEcCtD
Doxepin—Thrombocytopenia—Docetaxel—skin cancer	0.000139	0.00062	CcSEcCtD
Doxepin—ABCB1—head—skin cancer	0.000138	0.00272	CbGeAlD
Doxepin—Tachycardia—Docetaxel—skin cancer	0.000138	0.000618	CcSEcCtD
Doxepin—Skin disorder—Docetaxel—skin cancer	0.000138	0.000615	CcSEcCtD
Doxepin—Vomiting—Temozolomide—skin cancer	0.000135	0.000605	CcSEcCtD
Doxepin—Anorexia—Docetaxel—skin cancer	0.000135	0.000603	CcSEcCtD
Doxepin—Rash—Temozolomide—skin cancer	0.000134	0.0006	CcSEcCtD
Doxepin—Diarrhoea—Fluorouracil—skin cancer	0.000134	0.0006	CcSEcCtD
Doxepin—Dermatitis—Temozolomide—skin cancer	0.000134	0.0006	CcSEcCtD
Doxepin—Headache—Temozolomide—skin cancer	0.000133	0.000596	CcSEcCtD
Doxepin—Hypotension—Docetaxel—skin cancer	0.000132	0.000592	CcSEcCtD
Doxepin—Dizziness—Fluorouracil—skin cancer	0.00013	0.00058	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000129	0.000577	CcSEcCtD
Doxepin—Insomnia—Docetaxel—skin cancer	0.000128	0.000573	CcSEcCtD
Doxepin—Paraesthesia—Docetaxel—skin cancer	0.000127	0.000568	CcSEcCtD
Doxepin—Nausea—Temozolomide—skin cancer	0.000126	0.000565	CcSEcCtD
Doxepin—Dyspnoea—Docetaxel—skin cancer	0.000126	0.000564	CcSEcCtD
Doxepin—Somnolence—Docetaxel—skin cancer	0.000126	0.000563	CcSEcCtD
Doxepin—Vomiting—Fluorouracil—skin cancer	0.000125	0.000558	CcSEcCtD
Doxepin—Dyspepsia—Docetaxel—skin cancer	0.000125	0.000557	CcSEcCtD
Doxepin—Rash—Fluorouracil—skin cancer	0.000124	0.000553	CcSEcCtD
Doxepin—Dermatitis—Fluorouracil—skin cancer	0.000124	0.000553	CcSEcCtD
Doxepin—Decreased appetite—Docetaxel—skin cancer	0.000123	0.00055	CcSEcCtD
Doxepin—Headache—Fluorouracil—skin cancer	0.000123	0.00055	CcSEcCtD
Doxepin—Gastrointestinal disorder—Docetaxel—skin cancer	0.000122	0.000547	CcSEcCtD
Doxepin—Fatigue—Docetaxel—skin cancer	0.000122	0.000546	CcSEcCtD
Doxepin—Constipation—Docetaxel—skin cancer	0.000121	0.000541	CcSEcCtD
Doxepin—Pain—Docetaxel—skin cancer	0.000121	0.000541	CcSEcCtD
Doxepin—Feeling abnormal—Docetaxel—skin cancer	0.000117	0.000522	CcSEcCtD
Doxepin—Nausea—Fluorouracil—skin cancer	0.000117	0.000521	CcSEcCtD
Doxepin—Gastrointestinal pain—Docetaxel—skin cancer	0.000116	0.000518	CcSEcCtD
Doxepin—Abdominal pain—Docetaxel—skin cancer	0.000112	0.0005	CcSEcCtD
Doxepin—Body temperature increased—Docetaxel—skin cancer	0.000112	0.0005	CcSEcCtD
Doxepin—Hypersensitivity—Docetaxel—skin cancer	0.000104	0.000466	CcSEcCtD
Doxepin—Asthenia—Docetaxel—skin cancer	0.000102	0.000454	CcSEcCtD
Doxepin—Pruritus—Docetaxel—skin cancer	0.0001	0.000448	CcSEcCtD
Doxepin—ABCB1—lymph node—skin cancer	9.69e-05	0.00191	CbGeAlD
Doxepin—Diarrhoea—Docetaxel—skin cancer	9.69e-05	0.000433	CcSEcCtD
Doxepin—Dizziness—Docetaxel—skin cancer	9.36e-05	0.000419	CcSEcCtD
Doxepin—Vomiting—Docetaxel—skin cancer	9e-05	0.000403	CcSEcCtD
Doxepin—Rash—Docetaxel—skin cancer	8.93e-05	0.000399	CcSEcCtD
Doxepin—Dermatitis—Docetaxel—skin cancer	8.92e-05	0.000399	CcSEcCtD
Doxepin—Headache—Docetaxel—skin cancer	8.87e-05	0.000397	CcSEcCtD
Doxepin—Nausea—Docetaxel—skin cancer	8.41e-05	0.000376	CcSEcCtD
Doxepin—HRH2—Signaling by GPCR—KRAS—skin cancer	9.52e-06	0.000291	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—TERT—skin cancer	9.5e-06	0.000291	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—FOXO4—skin cancer	9.46e-06	0.00029	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—FOXO4—skin cancer	9.44e-06	0.000289	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—ERCC2—skin cancer	9.2e-06	0.000282	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—TERT—skin cancer	9.19e-06	0.000281	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—ENO2—skin cancer	9.11e-06	0.000279	CbGpPWpGaD
Doxepin—ADRA2C—Hemostasis—KRAS—skin cancer	9.11e-06	0.000279	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—TERT—skin cancer	9.09e-06	0.000278	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—ENO2—skin cancer	8.9e-06	0.000272	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—FOXO4—skin cancer	8.77e-06	0.000268	CbGpPWpGaD
Doxepin—ADRA2B—Hemostasis—TP53—skin cancer	8.67e-06	0.000265	CbGpPWpGaD
Doxepin—ADRA2A—Hemostasis—NRAS—skin cancer	8.6e-06	0.000263	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—TERT—skin cancer	8.55e-06	0.000262	CbGpPWpGaD
Doxepin—HTR6—Signaling by GPCR—NRAS—skin cancer	8.48e-06	0.00026	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—NRAS—skin cancer	8.43e-06	0.000258	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—ENO2—skin cancer	8.38e-06	0.000257	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—ENO2—skin cancer	8.31e-06	0.000254	CbGpPWpGaD
Doxepin—ADRA2B—Hemostasis—HRAS—skin cancer	8.29e-06	0.000254	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—ERCC2—skin cancer	8.14e-06	0.000249	CbGpPWpGaD
Doxepin—ADRA2C—Hemostasis—TP53—skin cancer	8.1e-06	0.000248	CbGpPWpGaD
Doxepin—HRH2—Signaling by GPCR—HRAS—skin cancer	8.09e-06	0.000248	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—CSPG4—skin cancer	8.06e-06	0.000247	CbGpPWpGaD
Doxepin—CHRM4—Signaling by GPCR—NRAS—skin cancer	8e-06	0.000245	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—BRAF—skin cancer	7.97e-06	0.000244	CbGpPWpGaD
Doxepin—ADRA2C—Hemostasis—HRAS—skin cancer	7.75e-06	0.000237	CbGpPWpGaD
Doxepin—HRH2—Signaling by GPCR—IL6—skin cancer	7.74e-06	0.000237	CbGpPWpGaD
Doxepin—HTR2B—Signaling by GPCR—NRAS—skin cancer	7.74e-06	0.000237	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—TERT—skin cancer	7.72e-06	0.000236	CbGpPWpGaD
Doxepin—CHRM5—Signaling by GPCR—NRAS—skin cancer	7.66e-06	0.000235	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—BRAF—skin cancer	7.52e-06	0.00023	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—ERCC2—skin cancer	7.47e-06	0.000229	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—TERT—skin cancer	7.45e-06	0.000228	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—TERT—skin cancer	7.41e-06	0.000227	CbGpPWpGaD
Doxepin—ADRA2A—Hemostasis—KRAS—skin cancer	7.4e-06	0.000227	CbGpPWpGaD
Doxepin—HTR6—Signaling by GPCR—KRAS—skin cancer	7.3e-06	0.000223	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—BRAF—skin cancer	7.28e-06	0.000223	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—KRAS—skin cancer	7.25e-06	0.000222	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—TERT—skin cancer	7.21e-06	0.000221	CbGpPWpGaD
Doxepin—ADRA1D—Signaling by GPCR—NRAS—skin cancer	7.2e-06	0.00022	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—BRAF—skin cancer	7.2e-06	0.00022	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.13e-06	0.000218	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—ENO2—skin cancer	7.1e-06	0.000217	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—TERT—skin cancer	7.1e-06	0.000217	CbGpPWpGaD
Doxepin—CHRM4—Signaling by GPCR—KRAS—skin cancer	6.89e-06	0.000211	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—BRAF—skin cancer	6.77e-06	0.000207	CbGpPWpGaD
Doxepin—HTR2B—Signaling by GPCR—KRAS—skin cancer	6.66e-06	0.000204	CbGpPWpGaD
Doxepin—CHRM5—Signaling by GPCR—KRAS—skin cancer	6.6e-06	0.000202	CbGpPWpGaD
Doxepin—ADRA2A—Hemostasis—TP53—skin cancer	6.58e-06	0.000201	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—TERT—skin cancer	6.54e-06	0.0002	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—NRAS—skin cancer	6.53e-06	0.0002	CbGpPWpGaD
Doxepin—ADRA2B—Signaling by GPCR—NRAS—skin cancer	6.5e-06	0.000199	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	6.5e-06	0.000199	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—TP53—skin cancer	6.45e-06	0.000197	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—TERT—skin cancer	6.44e-06	0.000197	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—TERT—skin cancer	6.42e-06	0.000197	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—TERT—skin cancer	6.4e-06	0.000196	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—TERT—skin cancer	6.38e-06	0.000195	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—TERT—skin cancer	6.32e-06	0.000193	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—TERT—skin cancer	6.3e-06	0.000193	CbGpPWpGaD
Doxepin—ADRA2A—Hemostasis—HRAS—skin cancer	6.29e-06	0.000193	CbGpPWpGaD
Doxepin—HTR1A—Signaling by GPCR—NRAS—skin cancer	6.28e-06	0.000192	CbGpPWpGaD
Doxepin—HTR2C—Signaling by GPCR—NRAS—skin cancer	6.25e-06	0.000191	CbGpPWpGaD
Doxepin—HTR6—Signaling by GPCR—HRAS—skin cancer	6.21e-06	0.00019	CbGpPWpGaD
Doxepin—ADRA1D—Signaling by GPCR—KRAS—skin cancer	6.2e-06	0.00019	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—HRAS—skin cancer	6.16e-06	0.000189	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—BRAF—skin cancer	6.11e-06	0.000187	CbGpPWpGaD
Doxepin—ADRA2C—Signaling by GPCR—NRAS—skin cancer	6.08e-06	0.000186	CbGpPWpGaD
Doxepin—ADRA1B—Signaling by GPCR—NRAS—skin cancer	5.98e-06	0.000183	CbGpPWpGaD
Doxepin—HTR6—Signaling by GPCR—IL6—skin cancer	5.94e-06	0.000182	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—BRAF—skin cancer	5.9e-06	0.000181	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—IL6—skin cancer	5.9e-06	0.000181	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—BRAF—skin cancer	5.87e-06	0.00018	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—TERT—skin cancer	5.86e-06	0.000179	CbGpPWpGaD
Doxepin—CHRM4—Signaling by GPCR—HRAS—skin cancer	5.85e-06	0.000179	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—BRAF—skin cancer	5.71e-06	0.000175	CbGpPWpGaD
Doxepin—HTR2B—Signaling by GPCR—HRAS—skin cancer	5.66e-06	0.000173	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—KRAS—skin cancer	5.62e-06	0.000172	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—BRAF—skin cancer	5.62e-06	0.000172	CbGpPWpGaD
Doxepin—CHRM5—Signaling by GPCR—HRAS—skin cancer	5.61e-06	0.000172	CbGpPWpGaD
Doxepin—CHRM4—Signaling by GPCR—IL6—skin cancer	5.6e-06	0.000171	CbGpPWpGaD
Doxepin—ADRA2B—Signaling by GPCR—KRAS—skin cancer	5.6e-06	0.000171	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	5.55e-06	0.00017	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—PTGS2—skin cancer	5.52e-06	0.000169	CbGpPWpGaD
Doxepin—DRD2—Signaling by GPCR—NRAS—skin cancer	5.51e-06	0.000169	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—ENO2—skin cancer	5.48e-06	0.000168	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—NRAS—skin cancer	5.42e-06	0.000166	CbGpPWpGaD
Doxepin—HTR2B—Signaling by GPCR—IL6—skin cancer	5.42e-06	0.000166	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—NRAS—skin cancer	5.41e-06	0.000166	CbGpPWpGaD
Doxepin—HTR1A—Signaling by GPCR—KRAS—skin cancer	5.4e-06	0.000165	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—NRAS—skin cancer	5.4e-06	0.000165	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—NRAS—skin cancer	5.38e-06	0.000165	CbGpPWpGaD
Doxepin—HTR2C—Signaling by GPCR—KRAS—skin cancer	5.38e-06	0.000165	CbGpPWpGaD
Doxepin—CHRM5—Signaling by GPCR—IL6—skin cancer	5.37e-06	0.000164	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—NRAS—skin cancer	5.33e-06	0.000163	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—NRAS—skin cancer	5.31e-06	0.000163	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—ERCC2—skin cancer	5.29e-06	0.000162	CbGpPWpGaD
Doxepin—ADRA1D—Signaling by GPCR—HRAS—skin cancer	5.27e-06	0.000161	CbGpPWpGaD
Doxepin—ADRA2C—Signaling by GPCR—KRAS—skin cancer	5.23e-06	0.00016	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—BRAF—skin cancer	5.18e-06	0.000159	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—ERCC2—skin cancer	5.17e-06	0.000158	CbGpPWpGaD
Doxepin—ADRA1B—Signaling by GPCR—KRAS—skin cancer	5.15e-06	0.000158	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—BRAF—skin cancer	5.1e-06	0.000156	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—BRAF—skin cancer	5.09e-06	0.000156	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—BRAF—skin cancer	5.07e-06	0.000155	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—BRAF—skin cancer	5.06e-06	0.000155	CbGpPWpGaD
Doxepin—ADRA1D—Signaling by GPCR—IL6—skin cancer	5.04e-06	0.000154	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—NRAS—skin cancer	5.01e-06	0.000153	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—BRAF—skin cancer	5.01e-06	0.000153	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—TP53—skin cancer	5e-06	0.000153	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—BRAF—skin cancer	4.99e-06	0.000153	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—NRAS—skin cancer	4.93e-06	0.000151	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—PTGS2—skin cancer	4.88e-06	0.000149	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—ERCC2—skin cancer	4.87e-06	0.000149	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—ERCC2—skin cancer	4.83e-06	0.000148	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—HRAS—skin cancer	4.78e-06	0.000146	CbGpPWpGaD
Doxepin—ADRA2B—Signaling by GPCR—HRAS—skin cancer	4.76e-06	0.000146	CbGpPWpGaD
Doxepin—DRD2—Signaling by GPCR—KRAS—skin cancer	4.74e-06	0.000145	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—NRAS—skin cancer	4.73e-06	0.000145	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—KRAS—skin cancer	4.67e-06	0.000143	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—KRAS—skin cancer	4.66e-06	0.000143	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—KRAS—skin cancer	4.64e-06	0.000142	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—BRAF—skin cancer	4.64e-06	0.000142	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—KRAS—skin cancer	4.63e-06	0.000142	CbGpPWpGaD
Doxepin—HTR1A—Signaling by GPCR—HRAS—skin cancer	4.59e-06	0.000141	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—KRAS—skin cancer	4.58e-06	0.00014	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—IL6—skin cancer	4.57e-06	0.00014	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—NRAS—skin cancer	4.57e-06	0.00014	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—KRAS—skin cancer	4.57e-06	0.00014	CbGpPWpGaD
Doxepin—HTR2C—Signaling by GPCR—HRAS—skin cancer	4.57e-06	0.00014	CbGpPWpGaD
Doxepin—ADRA2B—Signaling by GPCR—IL6—skin cancer	4.55e-06	0.000139	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—NRAS—skin cancer	4.53e-06	0.000139	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—PTGS2—skin cancer	4.48e-06	0.000137	CbGpPWpGaD
Doxepin—ADRA2C—Signaling by GPCR—HRAS—skin cancer	4.44e-06	0.000136	CbGpPWpGaD
Doxepin—HTR1A—Signaling by GPCR—IL6—skin cancer	4.4e-06	0.000135	CbGpPWpGaD
Doxepin—ADRA1B—Signaling by GPCR—HRAS—skin cancer	4.37e-06	0.000134	CbGpPWpGaD
Doxepin—HTR2C—Signaling by GPCR—IL6—skin cancer	4.37e-06	0.000134	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—KRAS—skin cancer	4.31e-06	0.000132	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—NRAS—skin cancer	4.26e-06	0.00013	CbGpPWpGaD
Doxepin—ADRA2C—Signaling by GPCR—IL6—skin cancer	4.25e-06	0.00013	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—KRAS—skin cancer	4.25e-06	0.00013	CbGpPWpGaD
Doxepin—ADRA1B—Signaling by GPCR—IL6—skin cancer	4.19e-06	0.000128	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—ERCC2—skin cancer	4.13e-06	0.000126	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—KRAS—skin cancer	4.07e-06	0.000125	CbGpPWpGaD
Doxepin—DRD2—Signaling by GPCR—HRAS—skin cancer	4.03e-06	0.000123	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—HRAS—skin cancer	3.97e-06	0.000121	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—HRAS—skin cancer	3.96e-06	0.000121	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—HRAS—skin cancer	3.95e-06	0.000121	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—KRAS—skin cancer	3.94e-06	0.00012	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—HRAS—skin cancer	3.93e-06	0.00012	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—HRAS—skin cancer	3.9e-06	0.000119	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—KRAS—skin cancer	3.9e-06	0.000119	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—HRAS—skin cancer	3.89e-06	0.000119	CbGpPWpGaD
Doxepin—DRD2—Signaling by GPCR—IL6—skin cancer	3.86e-06	0.000118	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—NRAS—skin cancer	3.84e-06	0.000118	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—TP53—skin cancer	3.83e-06	0.000117	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—IL6—skin cancer	3.8e-06	0.000116	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—IL6—skin cancer	3.79e-06	0.000116	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—IL6—skin cancer	3.78e-06	0.000116	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—IL6—skin cancer	3.77e-06	0.000115	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—IL6—skin cancer	3.73e-06	0.000114	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—IL6—skin cancer	3.72e-06	0.000114	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—NRAS—skin cancer	3.71e-06	0.000114	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—NRAS—skin cancer	3.69e-06	0.000113	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—HRAS—skin cancer	3.67e-06	0.000112	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—KRAS—skin cancer	3.66e-06	0.000112	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—TP53—skin cancer	3.62e-06	0.000111	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—HRAS—skin cancer	3.61e-06	0.00011	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—NRAS—skin cancer	3.59e-06	0.00011	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—NRAS—skin cancer	3.53e-06	0.000108	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—IL6—skin cancer	3.51e-06	0.000107	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—TP53—skin cancer	3.5e-06	0.000107	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—TP53—skin cancer	3.46e-06	0.000106	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—HRAS—skin cancer	3.46e-06	0.000106	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—IL6—skin cancer	3.46e-06	0.000106	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—HRAS—skin cancer	3.35e-06	0.000102	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—HRAS—skin cancer	3.31e-06	0.000101	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—IL6—skin cancer	3.31e-06	0.000101	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—KRAS—skin cancer	3.31e-06	0.000101	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—NRAS—skin cancer	3.26e-06	9.97e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—TP53—skin cancer	3.26e-06	9.96e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—NRAS—skin cancer	3.2e-06	9.81e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—IL6—skin cancer	3.2e-06	9.8e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—NRAS—skin cancer	3.2e-06	9.79e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—KRAS—skin cancer	3.19e-06	9.77e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—NRAS—skin cancer	3.19e-06	9.75e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—ERCC2—skin cancer	3.18e-06	9.74e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—NRAS—skin cancer	3.18e-06	9.72e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—KRAS—skin cancer	3.18e-06	9.72e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PTGS2—skin cancer	3.17e-06	9.72e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—IL6—skin cancer	3.17e-06	9.7e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—NRAS—skin cancer	3.15e-06	9.63e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—NRAS—skin cancer	3.14e-06	9.6e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—HRAS—skin cancer	3.11e-06	9.53e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PTGS2—skin cancer	3.1e-06	9.48e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—KRAS—skin cancer	3.09e-06	9.45e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—KRAS—skin cancer	3.04e-06	9.3e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—IL6—skin cancer	2.98e-06	9.12e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—TP53—skin cancer	2.94e-06	9e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PTGS2—skin cancer	2.92e-06	8.94e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—NRAS—skin cancer	2.92e-06	8.92e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PTGS2—skin cancer	2.89e-06	8.86e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—TP53—skin cancer	2.84e-06	8.68e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—TP53—skin cancer	2.82e-06	8.64e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—HRAS—skin cancer	2.81e-06	8.6e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—KRAS—skin cancer	2.8e-06	8.58e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—KRAS—skin cancer	2.76e-06	8.44e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—KRAS—skin cancer	2.75e-06	8.42e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—TP53—skin cancer	2.75e-06	8.4e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—KRAS—skin cancer	2.74e-06	8.4e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—KRAS—skin cancer	2.73e-06	8.37e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—HRAS—skin cancer	2.71e-06	8.3e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—KRAS—skin cancer	2.71e-06	8.29e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—TP53—skin cancer	2.7e-06	8.27e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—KRAS—skin cancer	2.7e-06	8.26e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—HRAS—skin cancer	2.7e-06	8.26e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—IL6—skin cancer	2.69e-06	8.23e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—HRAS—skin cancer	2.63e-06	8.04e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—IL6—skin cancer	2.6e-06	7.95e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—HRAS—skin cancer	2.58e-06	7.91e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—IL6—skin cancer	2.58e-06	7.91e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—IL6—skin cancer	2.51e-06	7.69e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—KRAS—skin cancer	2.51e-06	7.68e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—TP53—skin cancer	2.49e-06	7.62e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PTGS2—skin cancer	2.47e-06	7.57e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—IL6—skin cancer	2.47e-06	7.57e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—TP53—skin cancer	2.45e-06	7.5e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—TP53—skin cancer	2.45e-06	7.49e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—TP53—skin cancer	2.44e-06	7.46e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—TP53—skin cancer	2.43e-06	7.44e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—TP53—skin cancer	2.41e-06	7.37e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—TP53—skin cancer	2.4e-06	7.35e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—HRAS—skin cancer	2.38e-06	7.29e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—HRAS—skin cancer	2.34e-06	7.17e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—HRAS—skin cancer	2.34e-06	7.16e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—HRAS—skin cancer	2.33e-06	7.14e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—HRAS—skin cancer	2.32e-06	7.11e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—HRAS—skin cancer	2.3e-06	7.04e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—HRAS—skin cancer	2.3e-06	7.03e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—IL6—skin cancer	2.28e-06	6.98e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—IL6—skin cancer	2.24e-06	6.87e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—IL6—skin cancer	2.24e-06	6.85e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—IL6—skin cancer	2.23e-06	6.83e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—TP53—skin cancer	2.23e-06	6.83e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—IL6—skin cancer	2.22e-06	6.81e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—IL6—skin cancer	2.2e-06	6.74e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—IL6—skin cancer	2.2e-06	6.72e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—HRAS—skin cancer	2.13e-06	6.53e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—IL6—skin cancer	2.04e-06	6.25e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PTGS2—skin cancer	1.91e-06	5.84e-05	CbGpPWpGaD
